MedTrace Logo

Neuropathic Pain Syndrome Patient Study (MK-0000-072)

NCT00570310 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2015-05-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.

Conditions

  • Neuralgia, Postherpetic
  • Diabetic Neuropathy
  • Painful Small-Fiber Neuropathy
  • Idiopathic Distal Sensory Polyneuropathy

Interventions

DRUG

Comparator: pregabalin

pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks

DRUG

Comparator: Placebo (unspecified)

pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-09-30
Completion
2008-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00570310 on ClinicalTrials.gov